Downregulation of high mobility group box 1 enhances the radiosensitivity of non‑small cell lung cancer by acting as a crucial target of microRNA‑107

Bai,Lu; Zhang,Jingjing; Gao,Dongqi; Liu,Chengyi; Li,Wenxin; Li,Qingshan

doi:10.3892/etm.2021.10111

Downregulation of high mobility group box 1 enhances the radiosensitivity of non‑small cell lung cancer by acting as a crucial target of microRNA‑107

Authors:
- Lu Bai
- Jingjing Zhang
- Dongqi Gao
- Chengyi Liu
- Wenxin Li
- Qingshan Li
View Affiliations

Affiliations: Department of Oncology, Affiliated Hospital of Chengde Medical University, Chengde, Hebei 067000, P.R. China
Published online on: April 25, 2021 https://doi.org/10.3892/etm.2021.10111
Article Number: 679
Copyright: © Bai et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

High mobility group box 1 (HMGB1) has been reported to regulate the sensitivity of several types of cancer cell to chemoradiotherapy. The present study aimed to investigate the changes in HMGB1 expression after radiotherapy, as well as its regulatory role in the radiosensitivity of non‑small cell lung cancer (NSCLC) cells. The expression levels of HMGB1 in the serum of 73 patients with NSCLC were analyzed by ELISA. HMGB1 mRNA and microRNA (miR)‑107 expression in NSCLC cells were assessed using reverse transcription‑quantitative PCR. Receiver operating characteristic analysis was used to evaluate the diagnostic value of HMGB1. Cell counting kit‑8, Transwell invasion and clonogenic assays were used to determine cellular viability, invasiveness and colony formation ability, respectively. Following radiotherapy, the levels of HMGB1 were significantly decreased in the serum of patients with NSCLC, and lower serum levels had relatively high diagnostic accuracy in radiosensitive patients. Furthermore, HMGB1‑knockdown retarded cellular proliferation and invasion with or without irradiation, and enhanced NSCLC cell radiosensitivity. Furthermore, knocking down miR‑107 reversed the decreases in cellular proliferation and invasiveness both with and without irradiation, and reduced the survival fractions induced by sh‑HMGB1. HMGB1‑knockdown leads to radiosensitivity that may result from suppression of the Toll‑like receptor 4 (TLR4)/NF‑κB signaling pathway. Collectively, decreased expression of HMGB1 was found to be a putative diagnostic predictor of radiosensitivity in patients with NSCLC. HMGB1‑knockdown inhibited the proliferation and enhanced the radiosensitivity of NSCLC cells, which may be regulated via miR‑107 by mediating the TLR4/NF‑κB signaling pathway. Thus, HMGB1 may be a potential regulator of radioresistance in NSCLC, and the HMGB1/miR‑107 axis may represent a promising therapeutic target.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2019. CA Cancer J Clin. 69:7–34. 2019.PubMed/NCBI View Article : Google Scholar
2	Larsen JE and Minna JD: Molecular biology of lung cancer: Clinical implications. Clin Chest Med. 32:703–740. 2011.PubMed/NCBI View Article : Google Scholar
3	Zhao L, Wang J, Li H, Che J, Ma N and Cao B: Safety and Efficacy of Tianfoshen Oral Liquid in Non-Small Cell Lung Cancer Patients as an Adjuvant Therapy. Evid Based Complement Alternat Med. 2019(1375439)2019.PubMed/NCBI View Article : Google Scholar
4	Cheng P, Ma Y, Gao Z and Duan L: High Mobility Group Box 1 (HMGB1) Predicts Invasion and Poor Prognosis of Glioblastoma Multiforme via Activating AKT Signaling in an Autocrine Pathway. Med Sci Monit. 24:8916–8924. 2018.PubMed/NCBI View Article : Google Scholar
5	Hou C, Chen Y, Huang X, Huang Q, Li M and Tan X: miR-19 targets PTEN and mediates high mobility group protein B1(HMGB1)-induced proliferation and migration of human airway smooth muscle cells. PLoS One. 14(e0219081)2019.PubMed/NCBI View Article : Google Scholar
6	Yue Y, Zhou T, Gao Y, Zhang Z, Li L, Liu L, Shi W, Su L and Cheng B: High mobility group box 1/toll-like receptor 4/myeloid differentiation factor 88 signaling promotes progression of gastric cancer. Tumour Biol. 39(1010428317694312)2017.PubMed/NCBI View Article : Google Scholar
7	Chen R, Zhu S, Fan XG, Wang H, Lotze MT, Zeh HJ III, Billiar TR, Kang R and Tang D: High mobility group protein B1 controls liver cancer initiation through yes-associated protein-dependent aerobic glycolysis. Hepatology. 67:1823–1841. 2018.PubMed/NCBI View Article : Google Scholar
8	Huang CY, Chiang SF, Chen WT, Ke TW, Chen TW, You YS, Lin CY, Chao KSC and Huang CY: HMGB1 promotes ERK-mediated mitochondrial Drp1 phosphorylation for chemoresistance through RAGE in colorectal cancer. Cell Death Dis. 9(1004)2018.PubMed/NCBI View Article : Google Scholar
9	Shi Y and Gong W: Upregulation of miR-129-5p increases the sensitivity to Taxol through inhibiting HMGB1-mediated cell autophagy in breast cancer MCF-7 cells. Braz J Med Biol Res. 52(e8657)2019.PubMed/NCBI View Article : Google Scholar
10	Shrivastava S, Mansure JJ, Almajed W, Cury F, Ferbeyre G, Popovic M, Seuntjens J and Kassouf W: The Role of HMGB1 in Radioresistance of Bladder Cancer. Mol Cancer Ther. 15:471–479. 2016.PubMed/NCBI View Article : Google Scholar
11	Ma Y, Kang S, Wu X, Han B, Jin Z and Guo Z: Up-regulated HMGB1 in the pleural effusion of non-small cell lung cancer (NSCLC) patients reduces the chemosensitivity of NSCLC cells. Tumori. 104:338–343. 2018.PubMed/NCBI View Article : Google Scholar
12	Zheng H, Chen JN, Yu X, Jiang P, Yuan L, Shen HS, Zhao LH, Chen PF and Yang M: HMGB1 Enhances Drug Resistance and Promotes In Vivo Tumor Growth of Lung Cancer Cells. DNA Cell Biol. 35:622–627. 2016.PubMed/NCBI View Article : Google Scholar
13	Wu X, Wang W, Chen Y, Liu X, Wang J, Qin X, Yuan D, Yu T, Chen G, Mi Y, et al: High Mobility Group Box Protein 1 Serves as a Potential Prognostic Marker of Lung Cancer and Promotes Its Invasion and Metastasis by Matrix Metalloproteinase-2 in a Nuclear Factor-κB-Dependent Manner. Biomed Res Int. 2018(3453706)2018.PubMed/NCBI View Article : Google Scholar
14	Bai H and Wu S: miR-451: A Novel Biomarker and Potential Therapeutic Target for Cancer. Onco Targets Ther. 12:11069–11082. 2019.PubMed/NCBI View Article : Google Scholar
15	Chandan K, Gupta M and Sarwat M: Role of Host and Pathogen-Derived MicroRNAs in Immune Regulation During Infectious and Inflammatory Diseases. Front Immunol. 10(3081)2020.PubMed/NCBI View Article : Google Scholar
16	Chen G, Yu L, Dong H, Liu Z and Sun Y: MiR-182 enhances radioresistance in non-small cell lung cancer cells by regulating FOXO3. Clin Exp Pharmacol Physiol. 46(2):137–143. 2019.PubMed/NCBI View Article : Google Scholar
17	Li YH, Xu CL, He CJ, Pu HH, Liu JL and Wang Y: circMTDH.4/miR-630/AEG-1 axis participates in the regulation of proliferation, migration, invasion, chemoresistance, and radioresistance of NSCLC. Mol Carcinog. 59:141–153. 2020.PubMed/NCBI View Article : Google Scholar
18	Sun C, Zeng X, Guo H, Wang T, Wei L, Zhang Y, Zhao J, Ma X and Zhang N: MicroRNA-125a-5p modulates radioresistance in LTEP-a2 non-small cell lung cancer cells by targeting SIRT7. Cancer Biomark. 27:39–49. 2020.PubMed/NCBI View Article : Google Scholar
19	Xia H, Li Y and Lv X: MicroRNA-107 inhibits tumor growth and metastasis by targeting the BDNF-mediated PI3K/AKT pathway in human non-small lung cancer. Int J Oncol. 49:1325–1333. 2016.PubMed/NCBI View Article : Google Scholar
20	Zhang Z, Zhang L, Yin ZY, Fan XL, Hu B, Wang LQ and Zhang D: miR-107 regulates cisplatin chemosensitivity of A549 non small cell lung cancer cell line by targeting cyclin dependent kinase 8. Int J Clin Exp Pathol. 7:7236–7241. 2014.PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
22	Amornsupak K, Jamjuntra P, Warnnissorn M, O-Charoenrat P, Sa-Nguanraksa D, Thuwajit P, Eccles SA and Thuwajit C: High ASMA⁺ Fibroblasts and Low Cytoplasmic HMGB1⁺ Breast Cancer Cells Predict Poor Prognosis. Clin Breast Cancer. 17:441–452.e2. 2017.PubMed/NCBI View Article : Google Scholar
23	Suren D, Arda Gokay A and Sayiner A: High Mobility Group Box 1 (HMGB1) expression in gastric adenocarcinomas. J BUON. 23:422–427. 2018.PubMed/NCBI
24	Ohmori H, Luo Y, Fujii K, Sasahira T, Shimomoto T, Denda A and Kuniyasu H: Dietary linoleic acid and glucose enhances azoxymethane-induced colon cancer and metastases via the expression of high-mobility group box 1. Pathobiology. 77:210–217. 2010.PubMed/NCBI View Article : Google Scholar
25	Zhang X, Yang X, Zhu S, Li Q and Zou N: Radiosensitization of esophageal carcinoma cells by knockdown of HMGB1 expression. Oncol Rep. 41:1960–1970. 2019.PubMed/NCBI View Article : Google Scholar
26	Liu Q, Huo Y, Zheng H, Zhao J, Jia L and Wang P: Ethyl pyruvate suppresses the growth, invasion and migration and induces the apoptosis of non small cell lung cancer cells via the HMGB1/RAGE axis and the NF κB/STAT3 pathway. Oncol Rep. 42:817–825. 2019.PubMed/NCBI View Article : Google Scholar
27	Wang K, Shan S, Wang S, Gu X, Zhou X and Ren T: HMGB1-containing nucleosome mediates chemotherapy-induced metastasis of human lung cancer. Biochem Biophys Res Commun. 500:758–764. 2018.PubMed/NCBI View Article : Google Scholar
28	Wu L and Yang L: The function and mechanism of HMGB1 in lung cancer and its potential therapeutic implications. Oncol Lett. 15:6799–6805. 2018.PubMed/NCBI View Article : Google Scholar
29	Liu K, Huang J, Ni J, Song D, Ding M, Wang J, Huang X and Li W: MALAT1 promotes osteosarcoma development by regulation of HMGB1 via miR-142-3p and miR-129-5p. Cell Cycle. 16:578–587. 2017.PubMed/NCBI View Article : Google Scholar
30	Di X, He G, Chen H, Zhu C, Qin Q, Yan J, Zhang X and Sun X: High-mobility group box 1 protein modulated proliferation and radioresistance in esophageal squamous cell carcinoma. J Gastroenterol Hepatol. 34:728–735. 2019.PubMed/NCBI View Article : Google Scholar
31	Liu R, Chen Y, Shou T, Hu J and Qing C: miRNA-99b-5p targets FZD8 to inhibit non-small cell lung cancer proliferation, migration and invasion. Onco Targets Ther. 12:2615–2621. 2019.PubMed/NCBI View Article : Google Scholar
32	Wang L, Lv X, Fu X, Su L, Yang T and Xu P: miR-153 inhibits the resistance of lung cancer to gefitinib via modulating expression of ABCE1. Cancer Biomark. 25:361–369. 2019.PubMed/NCBI View Article : Google Scholar
33	Wu X, Ding N, Hu W, He J, Xu S, Pei H, Hua J, Zhou G and Wang J: Down-regulation of BTG1 by miR-454-3p enhances cellular radiosensitivity in renal carcinoma cells. Radiat Oncol. 9(179)2014.PubMed/NCBI View Article : Google Scholar
34	Lin SS, Yuan LJ, Niu CC, Tu YK, Yang CY and Ueng SWN: Hyperbaric oxygen inhibits the HMGB1/RAGE signaling pathway by upregulating mir-107 expression in human osteoarthritic chondrocytes. Osteoarthritis Cartilage. 27:1372–1381. 2019.PubMed/NCBI View Article : Google Scholar
35	Ai H, Zhou W, Wang Z, Qiong G, Chen Z and Deng S: MicroRNAs-107 inhibited autophagy, proliferation, and migration of breast cancer cells by targeting HMGB1. J Cell Biochem. Dec 2, 2018 (Epub ahead of print). doi: 10.1002/jcb.28157.
36	Chen G, Ward MF, Sama AE and Wang H: Extracellular HMGB1 as a proinflammatory cytokine. J Interferon Cytokine Res. 24:329–333. 2004.PubMed/NCBI View Article : Google Scholar
37	Li Z, Block MS, Vierkant RA, Fogarty ZC, Winham SJ, Visscher DW, Kalli KR, Wang C and Goode EL: The inflammatory microenvironment in epithelial ovarian cancer: A role for TLR4 and MyD88 and related proteins. Tumour Biol. 37:13279–13286. 2016.PubMed/NCBI View Article : Google Scholar
38	Bai M, Ma X, Li X, Wang X, Mei Q, Li X, Wu Z and Han W: The Accomplices of NF-κB Lead to Radioresistance. Curr Protein Pept Sci. 16:279–294. 2015.PubMed/NCBI View Article : Google Scholar
39	Jung CH, Han AR, Chung HJ, Ha IH and Um HD: Linarin inhibits radiation-induced cancer invasion by downregulating MMP-9 expression via the suppression of NF-κB activation in human non-small-cell lung cancer A549. Nat Prod Res. 33:3582–3586. 2019.PubMed/NCBI View Article : Google Scholar
40	Liu YC, Chiang IT, Hsu FT and Hwang JJ: Using NF-κB as a molecular target for theranostics in radiation oncology research. Expert Rev Mol Diagn. 12:139–146. 2012.PubMed/NCBI View Article : Google Scholar
41	Jiang C, Qu X, Ke H, Gong W, Chen R, Yang W and Cheng Z: Association between the HMGB1/TLR4 signaling pathway and the clinicopathological features of ovarian cancer. Mol Med Rep. 18:3093–3098. 2018.PubMed/NCBI View Article : Google Scholar
42	Tang H, Wang F, Zhou XF, Zhou J, Chen L, Luo JD and Xu EC: Relationship between TLR4 and NF-κB p65 protein expressions and clinical radiosensitivity of patients with esophageal squamous cell carcinoma. Pak J Med Sci. 30:982–985. 2014.PubMed/NCBI View Article : Google Scholar
43	Zhi-Feng W, Le-Yuan Z, Xiao-Hui Z, Ya-Bo G, Jian-Ying Z, Yong H and Zhao-Chong Z: TLR4-dependent immune response promotes radiation-induced liver disease by changing the liver tissue interstitial microenvironment during liver cancer radiotherapy. Radiat Res. 182:674–682. 2014.PubMed/NCBI View Article : Google Scholar